Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian

Metastatic Ovarian Cancer Clinical Trial

Official title:

A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03412526
• Other study ID #: SHEBA-16-3568-JS-TIL Ovarian
• Status: Recruiting
• Phase: Phase 2
• Start date: January 21, 2018
• Est. completion date: February 1, 2022

Study information

• Verified date: April 2019
• Source: Sheba Medical Center
• Contact: Jacob Scachter, Prof.
• Phone: 972-3-5304907
• Email: jacob.schachter[@]sheba.health.gov.il
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) in combination with lymphodepletion and high-dose interleukin 2.

Most TIL ACT trials have been conducted as salvage therapy for patients who already had failed numerous treatments; many study participants presented with multiple metastases, frequently in visceral organs and even in the brain. The effectiveness of TIL ACT in eradicating metastatic tumors of the responding patients underlines the value of this immunotherapeutic approach.

Recent developments in the identification and selection of tumor-specific T-cell populations have facilitated the implementation of TIL ACT also in nonmelanoma malignancies. Building on the experience of Ella Lemelbaum Institute, Sheba Medical Center with ACT TIL in the treatment of metastatic melanoma, the Dept. of Oncology, Tel HaShomer has expanded the use of TIL ACT following a reduced intensity, non-myeloablative, lymphodepleting induction regimen to metastatic Melanoma, Ovarian (OC) and Cervical cancer patients. The rationale supporting these studies is to further develop the ACT TIL procedure and expand its applicability to metastatic OC and cervical cancers.

Description:

The Sponsor is developing the ex-vivo expanded autologous Tumor Infiltrating Lymphocytes (TIL) as the Investigational Product (IP). Yet, the administration of the TIL cellular product can only be accomplished in the context of an Autologous, Adoptive Cell Therapy (ACT) procedure which is composed of the following steps:

1. Reduced Intensity, non-myeloablative, lymphodepleting induction regimen using Fludarabine (25 mg/m2 for 3 days) followed by Total Body Radiation (TBR) (2 Gray as a single treatment) for 1 day

2. Preparation and administration of unselected or 4-1BB enriched TIL

3. Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.

4. Early-stage follow-up until 30 days post-discharge

5. Late-stage follow-up, such as CT scans, will be carried out four and twelve weeks after TIL administration, and then every 3 months thereafter for the first year after TIL therapy; for the second year and onwards, as clinically indicated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: February 1, 2022
• Est. primary completion date: February 1, 2021
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 80 Years

Eligibility

INCLUSION CRITERIA

1. Able to understand and sign the Informed Consent Form.

2. Pathology confirmed epithelial Ovarian/Fallopian Tube/Primary Peritoneal carcinomatosis.

3. For ovarian/peritoneal carcinoma: Platinum- resistant or platinum refractory disease (platinum-resistant disease is defined as disease-progression within 6 months of completion of prior platinum containing regimen, whereas platinum refractory disease is defined as disease progression while on platinum containing regimen or within 3 months from first line, adjuvant chemotherapy).

4. Received and exhausted standard of care therapies for recurrent ovarian cancer and further chemotherapy lines have no proven added value. (For platinum resistant disease, received no more than 3 prior chemotherapy lines, whereas for platinum refractory disease received no more than 2 previous chemotherapy lines).

5. Patients must have at least one lesion that is resectable for TIL generation.

6. Have measurable disease per RECIST 1.1.

7. Patients with one or more brain metastases less than 1 cm each, and any patients with 1 or 2 brain metastases greater than 1 cm must have been treated and stable for 6 weeks.

8. Greater than or equal to 18 years of age.

9. For Patients with child bearing potential, willing to practice birth control from the start of chemotherapy until 120 days after release from the hospital.

10. Life expectancy of greater than three months

11. Performance status of ECOG 0 or 1

12. Adequate organ function defined by lab test results:

Hematology:

Absolute neutrophil count greater than 1000/mm3 without support of filgrastim Normal WBC greater than 3000/mm3. Hemoglobin greater than 9.0 g/dL Platelet count greater than 100,000/mm3

Serology:

Seronegative for HIV antibody. Seronegative for Hepatitis B or Hepatitis C (patients who recovered from previous infection and have no detected HBSAg or HCV RNA are allowed).

Chemistry:

Serum ALT/AST less than three times the upper limit of normal (ULN). Serum creatinine less than or equal to 1.6 mg/dL Total bilirubin no more than 1.5 times the ULN, except in patients with Gilbert's Syndrome who must have a total bilirubin less than 3 mg/dL.

13. Negative pregnancy test in women of child bearing potential.

14. More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients' toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo). Patients may have undergone minor surgical procedures with the past 3 weeks, as long as all toxicities have recovered to grade 1 or less.

Note: As described in the Study Population section in the synopsis, before entering the trial, the medical team will present other available experimental therapies to the patient for her consideration.

SUBJECT EXCLUSION CRITERIA

1. Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the non-myeloablative, lymphodepleting induction regimen on the fetus or infant. (Note: Pregnancies occurring in patients with Ovarian cancer are very rare, but possible. For this reason, ELIM has decided to retain the sections dealing with possible cases of pregnancy during the study.)

2. Systemic steroid therapy required (patients who require replacement therapy for adrenal insufficiency may be enrolled if steroid treatment dose do not exceed 10 mg of prednisone or equivalent).

3. Active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease.

4. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease and AIDS).

5. Opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)

6. History of severe immediate hypersensitivity reaction to any of the agents used in this study , including history of an anaphylactic reaction to penicillin or gentamicin

7. History of coronary revascularization or ischemic heart disease.

8. Any patient known to have an LVEF less than or equal to 50 percent.

9. Documented LVEF of less than or equal to 50 percent tested in patients with clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, second or third degree heart block

10. Documented FEV1 and DLCO (relative to predicted) less than or equal to 60 percent.

Related Conditions & MeSH terms

• Metastatic Ovarian Cancer

Intervention

Drug:
• Fludarabine
Reduced intensity, myeloablative, lymphodepleting regimen (25 mg/m2 for 3 days)

Radiation:
• Radiation
Total Body Radiation (TBR) (2 Gray in a single treatment) for 1 day

Biological:
• TIL administration
TIL Administration

Drug:
• IL-2
bolus high-dose (720,000 IU/kg) IL-2 is administered to the patients every 8 hours, to tolerance. A maximum of 10 doses are given to the patients.

Locations

Country	Name	City	State
Israel	Sheba medical Center	Ramat Gan

Sponsors (1)

Lead Sponsor	Collaborator
Sheba Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Tumor responses	Radiological follow up via CT to determine the sum of complete Responders (CR) + Partial Responders (PR) +Stable Disease (SD) as assessment by RECICT 1.1	3 years
Primary	Assess adverse events using NCI CTCAE V.4.03 during treatment and follow up	adverse events will be assess using MCI CTCAE V.4.03 during treatment and follow up	3 years
Secondary	Overall survival (OS)	Overall survival is defined as the time from study entry until death from any cause	3 years
Secondary	Response Rate( RR)	Radiological follow up via CT to determine the sum of complete responders (CR) + Partial responders (PR) as assessed by RECICT 1.1	3 years
Secondary	Progression Free Survival (PFS)	Progression free survival according to RECICT 1.1	3 years
Secondary	Quality of Life (QoL)	assessment of Quality of Life (QoL) using disease specific modules of the EORTC QLQ-C30 (version 3.0)	3 years